Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Identifying Heart, Lung, and Blood Disease-Causing Variants
The National Institutes of Health has formed a partnership with the National Heart, Lung, and Blood Institute to establish a program that aims to Identify Heart, Lung, and Blood Disease-Causing Variants.

---

Minor Use Minor Species Development of Drugs: Research Project Grant
The National Institutes of Health has partnered with the U.S. Food and Drug Administration (FDA) and the Center for Veterinary Medicine(CVM) in an effort to establish the Minor Use Minor Species Development of Drugs: Research Project Grant.

---

International Research Collaboration on Drug Abuse and Addiction
The National Institutes of Health, in collaboration with the National Institute on Drug Abuse (NIDA), has recently established the International Research Collaboration on Drug Abuse and Addiction Program wherein they seek to solicit collaborative research applications regarding addiction and drug use, through the utilization of special opportunities and resources that exist outside the United States of America.

---

OMICS Technologies For Predictive Modeling of Infectious Diseases Program
In keeping with this mission, the National Institutes of Health has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID) in an attempt to establish the OMICS Technologies For Predictive Modeling of Infectious Diseases Program.

---